Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Gene therapy can effectively treat mice with tuberous sclerosis complex, shows study

Patients with tuberous sclerosis complex, a genetic disorder characterized by the growth of noncancerous tumors in multiple organs of the body, have limited treatment options.

8 Jan 2021

Thermo Fisher announces construction of new cGMP plasmid DNA manufacturing facility

Thermo Fisher Scientific, the world leader in serving science, today announced the construction of a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif.

From Thermo Fisher Scientific Inc. 18 Dec 2020

New data shows encouraging results for patients with neuro-degenerative blinding eye disease

New data published in the Journal Science Translational Medicine shows encouraging results in a worldwide clinical trial for patients diagnosed with the neuro-degenerative blinding eye disease; Leber Hereditary Optic Neuropathy (LHON.)

16 Dec 2020

Interim results show Oxford COVID-19 vaccine protects against symptomatic disease

First full results from interim analysis confirm that the Oxford COVID-19 vaccine (AZD1222) has an acceptable safety profile and is efficacious against symptomatic COVID-19 disease, with no hospitalizations or severe disease reported in the COVID-19 vaccine group so far.

9 Dec 2020

A new potential COVID-19 vaccine candidate: YF-S0

A recent study published in the journal Nature describes the safety and efficacy of a live-attenuated yellow fever 17D (YF17D) vector-based vaccine candidate expressing a non-cleavable form of the spike protein of severe acute respiratory coronavirus 2 (SARS-CoV2).

2 Dec 2020

Genethon to start international clinical trial for treatment of Duchenne muscular dystrophy

Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular dystrophy with product GNT 004.

2 Dec 2020

Oxford University and AstraZeneca release their COVID-19 vaccine results

AstraZeneca and the University of Oxford have just released their results from its interim analysis of AZD1222, a vaccine being trialed to prevent COVID-19.

From AstraZeneca 23 Nov 2020

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

A team of scientists from the University of Oxford, UK, has revealed that site-specific glycosylation differs between spike proteins derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a viral vector-based vaccine candidate.

18 Nov 2020

Repairing brain damage caused by MS

Neurological symptoms as a result of Multiple Sclerosis (MS), such as loss of cognitive or motor function, lead to a great many problems for over 2.5 million people worldwide.

10 Nov 2020

UH and CWRU announce Phase 3 trial of Astrazeneca's investigational COVID-19 vaccine

University Hospitals and Case Western Reserve University announced today that UH Cleveland Medical Center has been selected as a clinical trial site for the Phase 3 global study of an investigational vaccine against SARS-CoV-2, sponsored by AstraZeneca.

29 Oct 2020

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

Design of an mRNA SARS-CoV-2 vaccine encapsulated in lipid nanoparticles

Now, a new study presented on the preprint server bioRxiv in October 2020 describes the efficient design of an mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on the use of the viral receptor-binding domain (RBD) mRNA encapsulated in lipid nanoparticles (LNP).

19 Oct 2020

Mass production of SARS-CoV-2 ORF8 protein using a chemical-inducible system in tobacco BY-2 cells

Researchers from the Japan Advanced Institute of Science and Technology (JAIST) and Ishikawa Prefectural University, Japan, recently attempted to synthesize the ORF8 protein with the help of a chemical-inducible protein production system using tobacco BY-2 cells. This study has been published demonstrated in the preprint server, bioRxiv.

9 Oct 2020

People infected with other types of coronaviruses may have less severe COVID-19 infection

Being previously infected with a coronaviruses that cause the "common cold" may decrease the severity of severe acute respiratory syndrome coronavirus (SARS-CoV-2) infections, according to results of a new study

7 Oct 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

OXGENE launches a scalable, plasmid-free manufacturing system for AAV

OXGENE™, a biotechnology company designing and developing scalable gene therapy technologies, has today announced the launch of its scalable, plasmid-free manufacturing system for AAV.

From OXGENE 23 Sep 2020

Oxford University and AstraZeneca resume COVID-19 vaccine trial

More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.

14 Sep 2020

Effective, simple, safe self-amplifying RNA vaccines

A recent review paper in the journal Current Opinion in Virology in September 2020 shows how a new generation of RNA vaccines called self-amplifying RNA vaccines are more potent than conventional mRNA vaccines and could hold the key to the global production of cost-effective potent COVID-19 vaccines.

11 Sep 2020

AstraZeneca COVID-19 vaccine trial paused due to suspected adverse reaction

The coronavirus disease (COVID-19) pandemic is rippling across the globe, with over 27.47 million reported cases. With the vast spread of the virus, scientists are racing to gain the approval of candidate vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 disease and Multisystem Inflammatory Syndrome in Children (MIS-C).

8 Sep 2020

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.

5 Sep 2020